Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

William H Ludlam

Showing results (21-30 of 27) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 27 results.
Pituitary|September 16, 2019
Development of a novel patient-reported measure for acromegaly: the Acro-TSQMaria Fleseriu, Leon Fogelfeld, Murray B Gordon, et al.
Pituitary|December 7, 2019
Observed discordance between outcomes reported by acromegaly patients and their treating endocrinology medical providerEliza B Geer, Jill Sisco, Daphne T Adelman, et al.
BMC Endocrine Disorders|August 2, 2020
Patient reported outcome data from acromegaly patients treated with injectable somatostatin receptor ligands (SRLs) in routine clinical practiceEliza B Geer, Jill Sisco, Daphne T Adelman, et al.
Frontiers in Endocrinology|April 1, 2021
Disease and Treatment-Related Burden in Patients With Acromegaly Who Are Biochemically Controlled on Injectable Somatostatin Receptor LigandsMaria Fleseriu, Mark Molitch, Alexander Dreval, et al.
European Journal of Endocrinology|September 29, 2022
Durable biochemical response and safety with oral octreotide capsules in acromegalySusan L Samson, Lisa B Nachtigall, Maria Fleseriu, et al.
The Journal of Clinical Endocrinology and Metabolism|September 4, 2020
Maintenance of Acromegaly Control in Patients Switching From Injectable Somatostatin Receptor Ligands to Oral OctreotideSusan L Samson, Lisa B Nachtigall, Maria Fleseriu, et al.
The Lancet. Diabetes & Endocrinology|December 26, 2021
Maintenance of response to oral octreotide compared with injectable somatostatin receptor ligands in patients with acromegaly: a phase 3, multicentre, randomised controlled trialMaria Fleseriu, Alexander Dreval, Irina Bondar, et al.
Pageof 3

Showing results (21-30 of 27) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 27 results.
Pituitary|September 16, 2019
Development of a novel patient-reported measure for acromegaly: the Acro-TSQMaria Fleseriu, Leon Fogelfeld, Murray B Gordon, et al.
Pituitary|December 7, 2019
Observed discordance between outcomes reported by acromegaly patients and their treating endocrinology medical providerEliza B Geer, Jill Sisco, Daphne T Adelman, et al.
BMC Endocrine Disorders|August 2, 2020
Patient reported outcome data from acromegaly patients treated with injectable somatostatin receptor ligands (SRLs) in routine clinical practiceEliza B Geer, Jill Sisco, Daphne T Adelman, et al.
Frontiers in Endocrinology|April 1, 2021
Disease and Treatment-Related Burden in Patients With Acromegaly Who Are Biochemically Controlled on Injectable Somatostatin Receptor LigandsMaria Fleseriu, Mark Molitch, Alexander Dreval, et al.
European Journal of Endocrinology|September 29, 2022
Durable biochemical response and safety with oral octreotide capsules in acromegalySusan L Samson, Lisa B Nachtigall, Maria Fleseriu, et al.
The Journal of Clinical Endocrinology and Metabolism|September 4, 2020
Maintenance of Acromegaly Control in Patients Switching From Injectable Somatostatin Receptor Ligands to Oral OctreotideSusan L Samson, Lisa B Nachtigall, Maria Fleseriu, et al.
The Lancet. Diabetes & Endocrinology|December 26, 2021
Maintenance of response to oral octreotide compared with injectable somatostatin receptor ligands in patients with acromegaly: a phase 3, multicentre, randomised controlled trialMaria Fleseriu, Alexander Dreval, Irina Bondar, et al.
Pageof 3